J B CHEMICALS AND PHARMA

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Successful US FDA inspection of API Manufacturing facility at Panoli, Gujarat '.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Notice in respect of transfer of equity shares of the Company to Investor Education and Protection Fund (IEPF). '.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Sub: Disclosure under Regulation 30 of SEBI (Listing Regulations and Disclosure Requirements), 2015Ref: Revocation of Closure Order for Formulations Facility at DamanWe refer to disclosure made on April 19, 2018 regarding an order from Office of Member Secretary, Pollution Control Committee, Daman directing the closure of the Company��s formulation manufacturing facility at Daman (��the said Closure order��). We now wish to inform you that the said Closure order has been revoked by the issuing authority. The Company h

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'The Company has received an order from Office of Member Secretary, Pollution Control Committee, Daman dated April 18, 2018 directing the closure of the Company��s formulation manufacturing facility at Daman (��the said order��) on the ground of alleged deviation of standards of treated waste water released from ETP outlet of the said facility. The Company does not accept the analytical results obtained by the said authority. The Company is taking all necessary steps so as to resume operations at the said facility in li

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Dear Sir,Sub: EU approval for manufacturing facilities at Panoli This is to inform you that Medicines Authority of Malta has accorded its approval to the Company��s manufacturing facilities at Panoli, Gujarat for tablets, capsules, liquids for internal use and semi-solids (i.e. topical preparations like Ointments, Creams and Gels). This approval is valid in entire European Union. This approval will not only help Company increase its product basket for this market but will also boost contra

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding 'Supplementary ANDA approval by US FDA '.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the company has fixed September 12, 2017 as cut off date to ascertain eligibility of the beneficial owners/shareholders of the Company's share to receive the dividend for FY 2016-17, if declared at the annual general Meeting.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of Notice in respect of transfer of equity shares of the Company to Investor Education and Protection Fund (IEPF).

JB Chemicals & Pharmaceuticals Limited has informed the Exchange vide letter dated July 18, 2016 regarding "Update on Order dated 8-1-2016 and 17-5-2016 passed by National Green Tribunal".

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Order dated January 8, 2016 of National Green Tribunal which, inter alia, directed the closure of industrial activities at Company s bulk drugs plant at Panoli, Gujarat, and various updates thereon disclosed from time to time. Further inform that the National Green Tribunal by Judgement and Order dated May 17, 2016 ( the said Order ) has not allowed the Company s Review Application. However, by Order dated May 18,2016, the National Green Tribunal has stayed the said Order for a period of 2 months to enable the Compa

JB Chemicals & Pharmaceuticals Limited has informed the Exchange the Update on Order of National Green Tribunal

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the stay on closure of bulk drugs plant of the company has been extended upto April 6, 2016.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange vide letter dated March 11, 2016 that " We refer to our disclosure under Regulation 30 of SEBI (Listing Regulations and Disclosure Requirements), 2015 made on 13-1-2016 and update thereon disclosed on 9-2-2016 and 4-3-2016. Further to the above, we wish to disclose that the direction regarding the closure of bulk drugs plant of the company has been stayed upto 18-3-2016".

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the company has filed the review petition before the National Green Tribunal, Pune and the direction regarding the closure of bulk drugs plant of the company has been stayed upto March 8, 2016.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding Disclosure under Regulation 30 (7) of SEBI (Listing Regulations and Disclosure Requirements), 2015

JB Chemicals & Pharmaceuticals Limited has informed the Exchange the Contact details of Key Managerial Personnel Pursuant to Regulation 30(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015,

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that the company has established its bulk drugs facility at GIDC Panoli and the said plant has been operating under valid environmental clearance. This facility has been accorded environmental clearance by the Ministry of Environment & Forest, Government of India.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of Notice of hearing of petition for Scheme of Amalgamation and Arrangement published in news papers.

JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange the outcome of meeting of equity shareholders convened under section 391 of the Companies Act, 1956-Clause 31(e) of the Listing Agreement.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per company's code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 1992, the trading window for dealing in the securities of the company will remain closed for all the directors/designated employees of the company from October 1, 2014 to November 11, 2014 (both days inclusive) in connection with approval of the unaudited financial results for the quarter ended on September 30, 2014.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per companys code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 1992, the trading window for dealing in the securities of the company will remain closed for all the directors/designated employees of the company from July 1, 2014 to August 6, 2014 (both days inclusive) in connection with approval of the unaudited financial results for the quarter ending on June 30, 2014.This closure of trading window has already been notified to all the directors/ designated employees on June 27, 2014

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that as per company s code of conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 1992, the trading window for dealing in the securities of the company has been closed for all the directors/designated employees of the company from April 1, 2014 to May 27, 2014 (both days inclusive) in relation to approval of audited financial results for the year ended on March 31, 2014.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that instead of re-opening the audited accounts for the year 2011-12 to reflect the adjustment of Rs. 64.50 crores, the company has now adjusted the said amount in the current financial year and the results for the quarter ended December 2013.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange vide letter dated October 30, 2013 regarding a Re-opening of audited accounts.

JB Chemicals & Pharmaceuticals Limited has informed the Exchange that With reference to the earlier announcement dated October 11, 2012 about receipt of notices of claim from Cilag GmbH International and Johnson & Johnson LLC entities under transaction documents in relation to sale of Russia-CIS OTC business, corresponding to the amount held in the Escrow Account & also reference to the earlier announcement dated February 11, 2013 informing about release of Rs. 25.24 crores to the Company from the Escrow Account. The Company has now informed the Exchange that Cilag GmbH International, Johnson

JB Chemicals & Pharmaceuticals Limited had informed the Exchange regarding the closure of the sale of Russia-CIS OTC business undertaking to Cilag GmbH International, a subsidiary of Johnson & Johnson, and the receipt of part consideration, and the balance being kept in the agreed Escrow Account. The Company also refer to letter dated October 11, 2012 informing the exchange about the receipt of claim from Johnson & Johnson group entities corresponding to the amount held in the Escrow Account. The Company would now like to inform that an amount of Rs. 25.24 crores has been released to the compa

Jb Chemicals & Pharmaceuticals Limited has informed the Exchange that with reference to the Company's earlier communication dated May 23, 2011 informing the Exchange about the company's sale of Russia-CIS OTC business undertaking to Cilag GmbH International, Switzerland, ('Cilag'), a subsidiary of Johnson & Johnson, and communication dated July 14, 2011 informing the Exchange about the closure of the said transaction and the receipt part from the consideration, the balance being kept in the agreed Escrow Account. The Company and its subsidiary have received claims by the Johnson & Johnson grou

Jb Chemicals & Pharmaceuticals Limited had informed the Exchange regarding the Company's decision to sell certain of its Russia-CIS prescription products business to Dr. Reddy's Laboratories Limited, Hyderabad (Dr. Reddy's) ("the Proposed Deal"). Further, the Company has now informed the Exchange that the Company as well as Dr. Reddy's have agreed with immediate effect not to pursue the Proposed Deal in their overall business interests. Accordingly, the Proposed Deal has been mutually called off. Consequently, the Company's subsidiary situated in Russia and Dr. Reddy's Russian subsidiary have

Jb Chemicals & Pharmaceuticals Limited has submitted to the Exchange brief details of Annual Accounts for the year ended on March 31, 2011.

Jb Chemicals & Pharmaceuticals Ltd. has submitted to the Exchange brief details of Annual Accounts for the year ended on March 31, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)<a href=/content/corporate/jbchem_account_15052009.zip target=NEW> For more details click here.</a>

Jb Chemicals & Pharmaceuticals Ltd. has submitted to the Exchange a copy of the Chairman's Letter to the Shareholders dated October 27, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/JBchemicals_Updates_05112008.zip target=NEW> For more details click here.</a>

Jb Chemicals & Pharmaceuticals Ltd. has submitted to the Exchange a copy of a Chairman's Speech delivered by Shri J. B. Mody, Chairman & Managing Director of the Company at the Annual General Meeting of the Company held on July 18, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/jbchem_UP_23072008.zip target=NEW> For more details click here.</a>

Jb Chemicals & Pharmaceuticals Ltd. had informed the Exchange that "This is with reference to the decision of the Board of Directors of the Company taken at its meeting held on April 8, 2008, approving a proposal for buy back of equity shares of the Company, a copy of which was filed with the Stock Exchanges vide its letter no. STOCKEXCHANGE\VP:MK\124, dated April 8, 2008 and the Public Notice published in the news papers on April 10, 2008 in compliance with the applicable Regulation(s) of the SEBI (Buy Back of Securities) Regulations 1998 thereafter". The Company has now informed the Exchange